戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ty of symptoms caused by statin tablets were nocebo.
2 Understanding the true nature of the placebo-nocebo complex and the scope of its effect in functional
3 g that side-effects comprise a psychosomatic nocebo component in vaccinated individuals.
4  We found that local application of an inert nocebo cream on the forearm increased pain ratings compa
5 benefits (placebo) and adverse side effects (nocebo) did not affect treatment expectations or adverse
6                                          The nocebo effect also has a major impact, as it accounts fo
7 ctive statin AEs, potentially related to the nocebo effect are reported more often by women than by m
8                                          The nocebo effect in motor performance consists in a reducti
9                                Conversely, a nocebo effect is when negative expectations from a subst
10 ctivation of the main effect of pain and the nocebo effect spatially overlapped.
11          The number of adverse events (i.e., nocebo effect) was also lower in the PCRS group, particu
12 hrough negative perceptions of generics (the nocebo effect), observational studies comparing brand-na
13  heighten anxiety and exacerbate pain (e.g., nocebo effect).
14                            We hypothesized a nocebo effect, whereby vaccine hesitancy towards the sec
15 ION: These analyses illustrate the so-called nocebo effect, with an excess rate of muscle-related AE
16 ated factors potentially associated with the nocebo effect.
17 rse effects (AEs) may be associated with the nocebo effect.
18 monstrated the importance of the placebo and nocebo effects across different diseases such as overact
19 active tDCS could 1) boost placebo and blunt nocebo effects and 2) modulate brain activity and connec
20 so describe barriers to vaccination, such as nocebo effects and antivaccination groups, and use lesso
21 dies of the relationship between placebo and nocebo effects and FND have focused on the use of placeb
22  for mechanistic manipulation of placebo and nocebo effects and may lead to improved clinical outcome
23 insights emphasise the significant impact of nocebo effects and stress the need to prioritise efforts
24  nonconscious conditioned stimuli on placebo/nocebo effects and the results challenge the exclusive r
25                                  Placebo and nocebo effects are associated with opposite responses of
26           These data reveal that placebo and nocebo effects are generated through differential engage
27 n increased understanding of how placebo and nocebo effects are produced and what biological and psyc
28 t the mechanisms responsible for placebo and nocebo effects can operate without conscious awareness o
29  suggests that fermentable carbohydrates and nocebo effects contribute considerably to symptom genera
30                                  Placebo and nocebo effects did not differ among drugs.
31 l relevance, the question of how placebo and nocebo effects differ in strength and duration remains l
32                       Harnessing placebo and nocebo effects has significant implications for research
33                              The placebo and nocebo effects highlight the importance of expectations
34                                  Placebo and nocebo effects illustrate the profound influence of cogn
35 nderscore the enduring nature of placebo and nocebo effects in pain, with nocebo responses demonstrat
36                In this cohort study, several nocebo effects occurred in the first week after COVID-19
37 the magnitude and persistence of placebo and nocebo effects on experimental pain.
38                                     We found nocebo effects on tolerability outcomes.
39  We assessed placebo effects on efficacy and nocebo effects on tolerability using random effects meta
40                     There may be placebo and nocebo effects present with its use.
41                                  Research on nocebo effects suggests that these concerns can amplify
42 puncture produced larger placebo and smaller nocebo effects than did pills for the treatment of hot f
43                            We expected these nocebo effects to be driven by (mis)information in males
44 treatments and in examining ways to minimize nocebo effects to improve clinical outcome.
45                      Significant placebo and nocebo effects were detected on days 1 and 8, but nocebo
46                      Significant placebo and nocebo effects were found in both experiment 1 (using cl
47  (RVM) pathway when both greater placebo and nocebo effects were observed.
48 o effects were detected on days 1 and 8, but nocebo effects were stronger on both test days.
49 be informative(2-4), research on placebo and nocebo effects(5-8) suggests that learning of one's gene
50 eralgesia, the most well-studied placebo and nocebo effects, are thought to initiate from the dorsal
51 e the mechanisms involved in the placebo and nocebo effects, including the central mechanism of expec
52                Previous studies suggest that nocebo effects, sometimes termed "negative placebo effec
53                                  Placebo and nocebo effects, the therapeutic and adverse effects, res
54 athological experiences, such as placebo and nocebo effects, wherein sensory information is shaped by
55 of a deeper link between FND and placebo and nocebo effects.
56 the role of indirect exposure in placebo and nocebo effects.
57 er, with a specific focus on the placebo and nocebo effects.
58 his is particularly relevant for placebo and nocebo effects.
59 orsal horn of the spinal cord, we combined a nocebo heat pain paradigm with spinal functional magneti
60 ring the generation of placebo analgesia and nocebo hyperalgesia in healthy human participants (N = 2
61                                              Nocebo hyperalgesia is an increase in subjective pain pe
62        In conclusion, we found evidence that nocebo hyperalgesia may be predominantly produced throug
63 odulatory phenomena of placebo analgesia and nocebo hyperalgesia remain to be directly addressed.
64 ment as expensive medication led to stronger nocebo hyperalgesia than labeling it as cheap medication
65  at the right DLPFC on placebo analgesia and nocebo hyperalgesia using a randomized, double-blind and
66 odel to investigate the neural substrates of nocebo hyperalgesia using heat pain on the right forearm
67                        Placebo analgesia and nocebo hyperalgesia, the most well-studied placebo and n
68 tivity associated with placebo analgesia and nocebo hyperalgesia.
69 e signal change during placebo analgesia and nocebo hyperalgesia.
70 ontal cortex mediated the effect of value on nocebo hyperalgesia.
71 with greater dlPFC and caudate activation to nocebo-induced itch also demonstrated greater dlPFC and
72                   Subjects reporting greater nocebo-induced itch also demonstrated greater placebo re
73 n insight to the brain mechanisms supporting nocebo-induced itch in AD, thus aiding our understanding
74               Brain activity likely supports nocebo-induced itch, but is currently unknown.
75 s related to dispositional traits and to the nocebo-induced reduction of force.
76                           This may reflect a nocebo mechanism, which may contribute to altered percep
77                                  Placebo and nocebo mechanisms, not well understood, are likely multi
78  also highly susceptible to both placebo and nocebo (negative placebo) effects.
79 ch relies mostly on the study of placebo and nocebo phenomena which influence physiological and patho
80 actors that appear to be associated with the nocebo phenomenon and/or reporting of nonspecific side e
81                                          The nocebo phenomenon, in which placebos produce adverse sid
82                            The corresponding nocebo ratio was 0.90.
83                        We also measured the "nocebo" ratio: the ratio of symptoms induced by taking s
84 sity ratings increased significantly more on nocebo regions compared with the control regions in whic
85                                  We compared nocebo-related subjective AEs with objective AEs and inv
86                The findings from placebo and nocebo research have important implications for the desi
87 placebo effects and reduce the impact of the nocebo response in clinical practice and suggest areas f
88 view discusses the impact of the placebo and nocebo response in health care.
89  personality traits and the magnitude of the nocebo response in motor performance.
90 eurobiological mechanisms of the placebo and nocebo response is required.
91 in the negative effects of treatments (ie, a nocebo response).
92 udy design and patient features with placebo/nocebo response.
93 strong placebo response while mitigating any nocebo response.
94 between placebo and vaccine arms showed that nocebo responses accounted for 76.0% of systemic AEs aft
95                                              Nocebo responses can explain some adverse clinical outco
96 ts, assessed whether conditioned placebo and nocebo responses could be triggered in response to nonco
97  of placebo and nocebo effects in pain, with nocebo responses demonstrating consistently greater stre
98 nsity ratings were collected and placebo and nocebo responses determined.
99      Additionally, we found that placebo and nocebo responses differentially activated the parabrachi
100          Systematic evidence regarding these nocebo responses in vaccine trials is important for COVI
101       To assess the magnitude of placebo and nocebo responses to ADHD and their association with acti
102      The nature and magnitude of placebo and nocebo responses to ADHD medications and the extent to w
103                fMRI analysis of hyperalgesic nocebo responses to identical calibrated noxious stimuli
104                                              Nocebo responses were associated with a deactivation of
105  high and low pain, could induce placebo and nocebo responses.
106 y be an unwitting contributor to placebo and nocebo responses.
107 ts might require more research to understand nocebo responses.
108                     Compared to open saline, nocebo saline demonstrated greater fMRI response in caud
109                                              Nocebo saline produced greater itch than open saline con
110       Our study demonstrates the capacity of nocebo saline to mimic both the sensory and neural effec
111 bject design, and contrast brain response to nocebo saline understood to be allergen vs open-label sa
112             Comparing pain stimulation under nocebo to a control pain stimulation of the same physica
113 eam, and also reduced pain thresholds on the nocebo-treated skin patch.
114 activated by cognitive manipulations such as nocebo treatments.
115                                  Placebo and nocebo use is common in practice.
116 s labeled lidocaine (placebo) and capsaicin (nocebo) were acting to modulate their pain relative to a

 
Page Top